



FOR IMMEDIATE RELEASE

PERRIGO AND GRACEWAY SETTLE LITIGATION AND NAME PERRIGO AS THE AUTHORIZED GENERIC DISTRIBUTOR FOR ALDARA®

ALLEGAN, Mich. – April 13, 2010 – Perrigo Company (Nasdaq: PRGO; TASE) and Graceway Pharmaceuticals, LLC., (based in Bristol, TN) today announced that they have entered into an agreement to settle all existing patent litigation regarding Perrigo’s ANDA filing No. 78-837 or generic imiquimod. As part of this agreement, Perrigo will be named Graceway’s authorized generic distributor for the Aldara® product through February 24, 2011 and, under certain circumstances, will be able to launch its own generic product after that date. Perrigo will begin shipping the authorized generic product within the next few weeks.

Aldara® (imiquimod) Cream 5% is indicated for the topical treatment of actinic keratoses on the face or scalp, superficial basal cell carcinoma, and external genital and perianal warts in patients 12 years old or older. Aldara had sales of approximately \$370 million for the 12 months ended February 2010, as measured by Wolters Kluwer Health.

Perrigo’s Chairman and CEO Joseph C. Papa concluded, “This agreement reflects our continuing investment in new products. Our generic pharmaceutical division is committed to participate in all new products in our extended topical category. As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders.”

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The Company’s primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (<http://www.perrigo.com>).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may

cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended June 27, 2009, as well as the Company’s subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Arthur J. Shannon, Vice President, Investor Relations and Communication
(269) 686-1709
E-mail: ajshannon@perrigo.com

Daniel B. Willard, Manager, Investor Relations and Communication
(269) 686-1597
E-mail: dbwillard@perrigo.com